185 related articles for article (PubMed ID: 34850536)
1. FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI; Selfe J; Aladowicz E; Man SYK; Bernauer C; Missiaglia E; Walters ZS; Gatz SA; Kelsey A; Generali M; Box G; Valenti M; de Haven-Brandon A; Galiwango D; Hayes A; Clarke M; Izquierdo E; Gonzalez De Castro D; Raynaud FI; Kirkin V; Shipley JM
Mol Oncol; 2022 Mar; 16(6):1272-1289. PubMed ID: 34850536
[TBL] [Abstract][Full Text] [Related]
2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
[TBL] [Abstract][Full Text] [Related]
3. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
4. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.
Chen G; Qiu H; Ke SD; Hu SM; Yu SY; Zou SQ
World J Gastroenterol; 2013 Apr; 19(16):2481-91. PubMed ID: 23674849
[TBL] [Abstract][Full Text] [Related]
5. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
6. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
[TBL] [Abstract][Full Text] [Related]
7. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
Mori M; Mori T; Yamamoto A; Takagi S; Ueda M
Hum Cell; 2019 Jul; 32(3):367-378. PubMed ID: 30963412
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
10. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Ware KE; Marshall ME; Heasley LR; Marek L; Hinz TK; Hercule P; Helfrich BA; Doebele RC; Heasley LE
PLoS One; 2010 Nov; 5(11):e14117. PubMed ID: 21152424
[TBL] [Abstract][Full Text] [Related]
11. FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1.
Huang T; Wang L; Liu D; Li P; Xiong H; Zhuang L; Sun L; Yuan X; Qiu H
Int J Oncol; 2017 May; 50(5):1501-1512. PubMed ID: 28339036
[TBL] [Abstract][Full Text] [Related]
12. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
[TBL] [Abstract][Full Text] [Related]
13. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
14. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor 7 Regulates Proliferation and Decidualization of Human Endometrial Stromal Cells via ERK and JNK Pathway in an Autocrine Manner.
Zhou WJ; Hou XX; Wang XQ; Li DJ
Reprod Sci; 2017 Dec; 24(12):1607-1619. PubMed ID: 28270036
[TBL] [Abstract][Full Text] [Related]
16. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
17. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
19. FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells.
Ropiquet F; Huguenin S; Villette JM; Ronflé V; Le Brun G; Maitland NJ; Cussenot O; Fiet J; Berthon P
Int J Cancer; 1999 Jul; 82(2):237-43. PubMed ID: 10389758
[TBL] [Abstract][Full Text] [Related]
20. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]